Background: Central serous chorioretinopathy (CSCR) is an idiopathic condition described by serous neurosensory retinal detachment at the posterior pole, usually associated with serous retinal pigment epithelial detachment (PED). CSCR patients as a rule have good visual prognosis. In most of the patients, CSCR is self-limiting and patients regain the last visual acuity. However, some patients may have visual disability due to permanent RPE and photoreceptor damage. Objective: The objective of the study is to determine the effect of intravitreal Bevacizumab in cases of chronic central serous chorioretinopathy in terms of mean change in central macular thickness. Study Design: Interventional experimental study. Settings: The study was conducted in Department of Ophthalmology, Allied Hospital, Faisalabad Pakistan. Duration: 2 years from January 2017 to December 2018. Methodology: An aggregate of 95 cases were recruited for the study. Study included both male and female patients with diagnosis of chronic CSCR (at least 6month duration). Best corrected visual acuity, Intra Ocular Pressure on Goldman applanation Tonometer and Optical coherence tomography on Optovue were recorded of both eye of all patients. Before starting the treatment, informed consent was signed by every patient and they were called on the day of injection. Intravitreal off label Bevacizumab (1.25/0.05ml) was given through pars plana in operation theater under aseptic conditions. After injection topical antibiotic drops were given to patients for one week and patients called for follow up after one week, one month, 2 month and 3 months. Same parameters BCVA, IOP, Dilated fundus examine and OCT was recorded on every visit. The final outcome i.e., change in central macular thickness was recorded. Results: In this study, out of 95 cases, 53.68%(n=51) were between 30-45 years of age while 46.32%(n=44) were between 46-60 years of age, mean ± SD was calculated as 46.83+7.82 years, 74.74%(n=71) were male and 25.26%(n=24) were females. Pre-treatment mean central macular thickness was recorded as 344.77+14.61µ which reduced to 154.57+16.57 µ, mean difference was recorded as 190.2+21.46 µ, p value was 0.0001 showing a significant difference. Conclusion: We concluded that intravitreal Bevacizumab significantly reduced central macular thickness in cases of chronic central serous chorioretinopathy.

Background: Color vision is an integral part of visual functions. Defective color vision may leadto difficulties in daily activities and even choosing and continuing in a certain profession. Colorvision deficiency or blindness may be congenital or acquired due to retinal or optic nerve disorders Aim: To investigate the frequency of color blindness or weakness in driving license candidates presenting for medical exam, for the year 2019. Methodology: The study design was descriptive cross sectional and the sampling technique wasnon probability convenient sampling. The place of study was eye outdoor of Allied Hospital,Faisalabad. The sample size was 13,637 based on inclusion criteria. The subjects ranged in agefrom 18 years onwards to a maximum presentation of 76 years with mean age as 30.728 ±10.131.Both genders were included in the study. Visual acuity was tested on Snellen’s Chart andrefraction, if needed, was performed to obtain best corrected acuity. Results: The results of the study showed that most of the subjects had 6/6 vision as 96.6% in righteye and 96.5% in left eye, 6/9 as 2.8% and 2.9% and 6/12 as 0.3% and 0.4% respectively for rightand left eye. The frequency of normal color vision was 94%, 4.9% for red green deficiency and 1.1% for color blindness. Conclusion: A frequency of 4.9% and 1.1% for color deficiency and color blindness respectively, in drivers, indicates that color vision must be tested to avoid any possible accidents related todeficient color perception. Keywords: Driving license, colorblindness